Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
20 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Xiber Science GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Xiber Science GmbH - Product Pipeline Review - 2014', provides an overview of the Xiber Science GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Xiber Science GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Xiber Science GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Xiber Science GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Xiber Science GmbH's pipeline products Reasons to buy - Evaluate Xiber Science GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Xiber Science GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Xiber Science GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Xiber Science GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Xiber Science GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Xiber Science GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Xiber Science GmbH Snapshot 4 Xiber Science GmbH Overview 4 Key Information 4 Key Facts 4 Xiber Science GmbH - Research and Development Overview 5 Key Therapeutic Areas 5 Xiber Science GmbH - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Xiber Science GmbH - Pipeline Products Glance 9 Xiber Science GmbH - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Xiber Science GmbH - Drug Profiles 11 Xib-1301 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Xib-05 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Xib-1302 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Xib-1303 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Xib-1304 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Xiber Science GmbH - Pipeline Analysis 16 Xiber Science GmbH - Pipeline Products by Route of Administration 16 Xiber Science GmbH - Pipeline Products by Molecule Type 17 Xiber Science GmbH - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables Xiber Science GmbH, Key Information 4 Xiber Science GmbH, Key Facts 4 Xiber Science GmbH - Pipeline by Indication, 2014 6 Xiber Science GmbH - Pipeline by Stage of Development, 2014 7 Xiber Science GmbH - Monotherapy Products in Pipeline, 2014 8 Xiber Science GmbH - Preclinical, 2014 9 Xiber Science GmbH - Discovery, 2014 10 Xiber Science GmbH - Pipeline by Route of Administration, 2014 16 Xiber Science GmbH - Pipeline by Molecule Type, 2014 17
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.